Clinical Trial Update: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy [Phase 3]

View source ↗

Summary

A Phase 3 study comparing cabozantinib in combination with atezolizumab versus sorafenib as first-line therapy for advanced hepatocellular carcinoma has posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Nexavar (Sorafenib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Exelixis | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-11